Coumarin Derivatives as Anticancer Agents for Lung Cancer Therapy: A Review

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Lung cancer accounts for 14% of new cancer diagnoses globally.
• Existing lung cancer drugs often cause significant side effects and multidrug resistance (MDR).
• There is a critical need for novel anticancer agents with improved safety and efficacy profiles.

Purpose of the Study:

• To review coumarin derivatives as potential inhibitors of key proteins implicated in lung cancer.
• To explore the structure-activity relationships (SAR) of coumarin derivatives for lung cancer treatment.
• To compile synthetic strategies and mechanisms of action for coumarin-based lung cancer therapies.

Main Methods:

• Literature survey of online databases (SciFinder, PubMed, EMBL, Scopus, Google Scholar).
• Analysis of structure-activity relationships (SAR) of coumarin derivatives.
• Compilation of synthetic routes and mechanisms of action.

Main Results:

• Coumarin derivatives show potential as inhibitors of various lung cancer-associated proteins (e.g., EGFR, tyrosine kinase, STAT).
• Specific substitutions on the coumarin nucleus, including N-aryl carboxamide, phenyl at C-3, and triazolyl/trihydroxystilbene/amino at C-4, enhance anticancer activity.
• Identified key structural features for effective targeting of lung cancer.

Conclusions:

• Coumarin derivatives represent a promising class of compounds for lung cancer management.
• Understanding SAR is crucial for designing novel, effective, and safer lung cancer therapeutics.
• This review synthesizes current knowledge on coumarin derivatives for lung cancer treatment.